AL Amyloidosis Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Janssen Pharma, Prothena, Alexion Pharma, Alnylam Pharma, Attralus, Neurimmune AG

DelveInsight's "AL Amyloidosis Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the AL Amyloidosis, historical and forecasted epidemiology as well as the AL Amyloidosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

To Know in detail about the AL Amyloidosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; AL Amyloidosis Market Forecast
https://www.delveinsight.com/sample-request/al-amyloidosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the AL Amyloidosis Market Report:
• The AL Amyloidosis market size was valued approximately USD 920 Million in the year 2021 and is anticipated to grow with a significant CAGR during the study period (2020-2033)
• In March 2025, Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leader in RNAi therapeutics, has announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for AMVUTTRA® (vutrisiran). This RNAi therapy is now approved for treating cardiomyopathy associated with wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults, aiming to reduce cardiovascular-related deaths, hospitalizations, and urgent heart failure visits. With this approval, AMVUTTRA becomes the first and only FDA-approved treatment for both ATTR-CM and the polyneuropathy linked to hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.
• In January 2025, Attralus, Inc., a clinical-stage biopharmaceutical company focused on advancing treatments for systemic amyloidosis, in collaboration with Brigham and Women's Hospital in Boston, MA, has announced the enrollment of the first patient in the Phase 3 REVEAL study. This clinical trial evaluates the investigational diagnostic imaging agent, 124I-evuzamitide (AT-01), in individuals suspected of having cardiac amyloidosis. The study aims to assess the sensitivity and specificity of 124I-evuzamitide in accurately diagnosing cardiac amyloidosis.
• AL amyloidosis is a rare disease, translating to ~8,500 new cases per year in the 7MM. This disease presents in older adults, median age 64, with slight male predominance (54%). According to the Amyloidosis Foundation, AL amyloidosis is the most common type, with approximately 4,500 new cases diagnosed every year in the United States
• In 2021, the total incident cases of AL Amyloidosis were the highest in the US, with nearly 4,500 cases, and the lowest in Spain with approximately 400 cases
• The epidemiology of AL Amyloidosis was divided based on total incidence, gender-specific cases, and age-specific cases. In 2021, Japan accounted for more than 500 incident cases for AL Amyloidosis
• Among EU5 countries, Germany had the highest number of incident cases of AL Amyloidosis (>900 cases) in 2021
• Key AL Amyloidosis Companies: Janssen Pharmaceuticals, Prothena, Alexion Pharmaceuticals, Alnylam Pharmaceuticals, Attralus, Neurimmue AG, Sorrento Therapeutics, Zentalis Pharmaceuticals, Sanofi, Astellas Pharma GmbH, GlaxoSmithKline, Takeda Oncology, and others
• Key AL Amyloidosis Therapies: Daratumumab, Birtamimab, CAEL-101, Vutrisiran, AT-03, NI006, STI-6129, ZN d5, Isatuximab, Bendamustine, Belantamab mafodotin, xazomib, and others
• The AL Amyloidosis epidemiology based on gender analyzed that there are slightly more cases in males than females in the United States
• The AL Amyloidosis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage AL Amyloidosis pipeline products will significantly revolutionize the AL Amyloidosis market dynamics.

AL Amyloidosis Overview
AL amyloidosis, also known as primary amyloidosis, is a rare and serious disease caused by the abnormal deposition of amyloid proteins in various tissues and organs. The "AL" stands for "amyloid light chain," which refers to the type of protein involved.

Get a Free sample for the AL Amyloidosis Market Report:
https://www.delveinsight.com/report-store/al-amyloidosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

AL Amyloidosis Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

AL Amyloidosis Epidemiology Segmentation:
The AL Amyloidosis market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of AL Amyloidosis
• Prevalent Cases of AL Amyloidosis by severity
• Gender-specific Prevalence of AL Amyloidosis
• Diagnosed Cases of Episodic and Chronic AL Amyloidosis

Download the report to understand which factors are driving AL Amyloidosis epidemiology trends @ AL Amyloidosis Epidemiology Forecast
https://www.delveinsight.com/sample-request/al-amyloidosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

AL Amyloidosis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the AL Amyloidosis market or expected to get launched during the study period. The analysis covers AL Amyloidosis market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the AL Amyloidosis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

AL Amyloidosis Therapies and Key Companies
• Daratumumab: Janssen Pharmaceuticals
• Birtamimab: Prothena
• CAEL-101: Alexion Pharmaceuticals
• Vutrisiran: Alnylam Pharmaceuticals
• AT-03: Attralus
• NI006: Neurimmue AG
• STI-6129: Sorrento Therapeutics
• ZN d5: Zentalis Pharmaceuticals
• Isatuximab: Sanofi
• Bendamustine: Astellas Pharma GmbH
• Belantamab mafodotin: GlaxoSmithKline
• xazomib: Takeda Oncology

Discover more about therapies set to grab major AL Amyloidosis market share @ AL Amyloidosis Treatment Market
https://www.delveinsight.com/sample-request/al-amyloidosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

AL Amyloidosis Market Strengths
• Recent launch of approved therapies and robust pipeline of innovative, first-in-class therapies are likely to boost AL amyloidosis market
• Improved awareness in recent years is leading to increasing disease incidence
• Collaboration between major market players (Commercialization of Darzalex Faspro by Genmab and Janssen Biotech, acquisition of Caelum biosciences by AstraZeneca in 2021) is expected to drive market growth

AL Amyloidosis Market Opportunities
• The friendly regulatory policies with orphan drug benefit, limited competition, high disease burden, are glittering opportunities for upcoming market players
• Drugs that can offer survival benefits for high-risk patients with good
• QALYs remains largely an unmet need
• The treatment of newly diagnosed AL in the future will likely include daratumumab-based therapy in conjunction with fibril-directed therapy which targets the amyloid protein already deposited in the heart. Their combination has the potential to improve outcomes in future

Scope of the AL Amyloidosis Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key AL Amyloidosis Companies: Janssen Pharmaceuticals, Prothena, Alexion Pharmaceuticals, Alnylam Pharmaceuticals, Attralus, Neurimmue AG, Sorrento Therapeutics, Zentalis Pharmaceuticals, Sanofi, Astellas Pharma GmbH, GlaxoSmithKline, Takeda Oncology, and others
• Key AL Amyloidosis Therapies: Daratumumab, Birtamimab, CAEL-101, Vutrisiran, AT-03, NI006, STI-6129, ZN d5, Isatuximab, Bendamustine, Belantamab mafodotin, xazomib, and others
• AL Amyloidosis Therapeutic Assessment: AL Amyloidosis current marketed and AL Amyloidosis emerging therapies
• AL Amyloidosis Market Dynamics: AL Amyloidosis market drivers and AL Amyloidosis market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• AL Amyloidosis Unmet Needs, KOL's views, Analyst's views, AL Amyloidosis Market Access and Reimbursement

To know more about AL Amyloidosis companies working in the treatment market, visit @ AL Amyloidosis Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/al-amyloidosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. AL Amyloidosis Market Report Introduction
2. Executive Summary for AL Amyloidosis
3. SWOT analysis of AL Amyloidosis
4. AL Amyloidosis Patient Share (%) Overview at a Glance
5. AL Amyloidosis Market Overview at a Glance
6. AL Amyloidosis Disease Background and Overview
7. AL Amyloidosis Epidemiology and Patient Population
8. Country-Specific Patient Population of AL Amyloidosis
9. AL Amyloidosis Current Treatment and Medical Practices
10. AL Amyloidosis Unmet Needs
11. AL Amyloidosis Emerging Therapies
12. AL Amyloidosis Market Outlook
13. Country-Wise AL Amyloidosis Market Analysis (2020-2034)
14. AL Amyloidosis Market Access and Reimbursement of Therapies
15. AL Amyloidosis Market Drivers
16. AL Amyloidosis Market Barriers
17. AL Amyloidosis Appendix
18. AL Amyloidosis Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Related Reports:

AL Amyloidosis Pipeline https://www.delveinsight.com/report-store/al-amyloidosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"AL Amyloidosis Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the AL Amyloidosis market. A detailed picture of the AL Amyloidosis pipeline landscape is provided, which includes the disease overview and AL Amyloidosis treatment guidelines.

AL Amyloidosis Epidemiology https://www.delveinsight.com/report-store/al-amyloidosis-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'AL Amyloidosis Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted AL Amyloidosis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports by DelveInsight
• Transcatheter Heart Valve Replacement Devices Market: https://www.delveinsight.com/report-store/transcatheter-aortic-valve-replacement-market
• Bone Neoplasms Market: https://www.delveinsight.com/blog/bone-cancer-treatment-market
• Peak Flow Meters Market: https://www.delveinsight.com/report-store/peak-flow-meters-market
• Neuroendoscopy Market: https://www.delveinsight.com/report-store/neuroendoscopy-market
• Nosocomial Infections Market: https://www.delveinsight.com/report-store/nosocomial-infections-market

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.